Samer Kasbari is an Oncology physician affiliated with Southeastern Medical Oncology Center. OpenAlex indexes 30 publications with 803 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
6 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
40.9%PD-1 inhibitor25%Pembrolizumab51%Nivolumab48%Keytruda0%Tecentriq0%Part D + Part B<11 patientsPlatinum-based Drug14.2%Oxaliplatin98%Carboplatin2%Part B, office-administered≥17 patients+ 9 more classes in this area
Blood & clotting
25.8%Erythropoiesis-stimulating Agent17.7%Darbepoetin alfa100%Part B, office-administered≥19 patientsIron, parenteral preparations7.9%Ferric derisomaltose100%Part B, office-administered≥58 patients+ 2 more classes in this area
Musculoskeletal
17.8%RANK Ligand Inhibitor17.5%Denosumab100%Prolia1%Part D + Part B≥147 patientsBisphosphonate0.4%Zoledronic acid100%Part B, office-administered≥49 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”